INSULIN GLARGINE MARKET ANALYSIS

Insulin Glargine Market, By Type (Lantus, Basaglar, Toujeo, Soliqua/Suliqua, Others), By Diabetes Type (Type 2 Diabetes, Type 1 Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024
Code : CMI5231
Pages :167
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Insulin Glargine Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Increase in demand for insulin glargine

Increasing use of insulin glargine across the globe is expected to boost the growth of the global insulin glargine market during the forecast period. Insulin glargine is a self-injectable solution that is used to control high blood sugar (hyperglycemia) in individuals with type 1 and 2 diabetes, and therefore, the use of insulin glargine has increased worldwide. In November 2021, Viatris Inc. and Biocon Biologics Ltd. announced the U.S. launch of SEMGLEE (insulin glargine-yfgn) injection, and Insulin Glargine (insulin glargine-yfgn) injection to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

Key Players Insights